391 related articles for article (PubMed ID: 14604497)
21. The role of UFT in metastatic colorectal cancer.
Bennouna J; Saunders M; Douillard JY
Oncology; 2009; 76(5):301-10. PubMed ID: 19299903
[TBL] [Abstract][Full Text] [Related]
22. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.
Meropol NJ; Sonnichsen DS; Birkhofer MJ; Ferreira I; Noel D
Cancer Chemother Pharmacol; 1999; 43(3):221-6. PubMed ID: 9923552
[TBL] [Abstract][Full Text] [Related]
23. Capecitabine for the treatment of advanced gastric cancer.
Norman G; Soares M; Peura P; Rice S; Suh D; Wright K; Sculpher M; Eastwood A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):11-7. PubMed ID: 21047486
[TBL] [Abstract][Full Text] [Related]
24. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
Borner MM; Schoffski P; de Wit R; Caponigro F; Comella G; Sulkes A; Greim G; Peters GJ; van der Born K; Wanders J; de Boer RF; Martin C; Fumoleau P
Eur J Cancer; 2002 Feb; 38(3):349-58. PubMed ID: 11818199
[TBL] [Abstract][Full Text] [Related]
25. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
Almond J; Ralston S
Br J Cancer; 2007 May; 96(9):1489; author reply 1490. PubMed ID: 17437019
[No Abstract] [Full Text] [Related]
26. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
[TBL] [Abstract][Full Text] [Related]
27. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
Twelves CJ
Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
[TBL] [Abstract][Full Text] [Related]
28. A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America.
Murad A; de Andrade CA; Delfino C; Arikian S; Doyle J; Sinha N
Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):128-35. PubMed ID: 9348585
[TBL] [Abstract][Full Text] [Related]
29. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
Cassidy J; Douillard JY; Twelves C; McKendrick JJ; Scheithauer W; Bustová I; Johnston PG; Lesniewski-Kmak K; Jelic S; Fountzilas G; Coxon F; Díaz-Rubio E; Maughan TS; Malzyner A; Bertetto O; Beham A; Figer A; Dufour P; Patel KK; Cowell W; Garrison LP
Br J Cancer; 2006 Apr; 94(8):1122-9. PubMed ID: 16622438
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
Nakayama T; Noguchi S
Oncologist; 2010; 15(1):26-36. PubMed ID: 20080863
[TBL] [Abstract][Full Text] [Related]
31. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
32. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
33. Practical considerations in the use of oral fluoropyrimidines.
Hoff PM
Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
[TBL] [Abstract][Full Text] [Related]
34. Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan.
Takata K; Fujita KI; Kubota Y; Ishida H; Ichikawa W; Shimada K; Sekikawa T; Taki-Takemoto I; Kamei D; Iwai S; Sasaki Y
J Pharm Health Care Sci; 2016; 2():30. PubMed ID: 27843573
[TBL] [Abstract][Full Text] [Related]
35. [Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Croockewit AJ; de Boer JE; van Loenhout JW; Koopmans PP
Ned Tijdschr Geneeskd; 2002 Jun; 146(24):1117-20. PubMed ID: 12092301
[TBL] [Abstract][Full Text] [Related]
36. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Van Cutsem E; Hoff PM; Harper P; Bukowski RM; Cunningham D; Dufour P; Graeven U; Lokich J; Madajewicz S; Maroun JA; Marshall JL; Mitchell EP; Perez-Manga G; Rougier P; Schmiegel W; Schoelmerich J; Sobrero A; Schilsky RL
Br J Cancer; 2004 Mar; 90(6):1190-7. PubMed ID: 15026800
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy for colorectal cancer.
Goyle S; Maraveyas A
Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
[TBL] [Abstract][Full Text] [Related]
38. Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.
Lin JK; Tan EC; Yang MC
Health Qual Life Outcomes; 2015 May; 13():61. PubMed ID: 25986478
[TBL] [Abstract][Full Text] [Related]
39. Oral 5-FU analogues in the treatment of breast cancer.
Bunnell CA; Winer EP
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):39-43. PubMed ID: 9830624
[TBL] [Abstract][Full Text] [Related]
40. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
